Biotech · Private company
Meissa Vaccines, Inc.
Track this companyFree. Adds Meissa Vaccines, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- Investigational RSV vaccine MV-012-968 (Dosage 1)Phase 1 · Respiratory Syncytial Virus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Investigational RSV vaccine MV-012-968 (Dosage 1)Phase 1 · Respiratory Syncytial Virus (RSV)ClinicalTrials.gov · fetched Nov 12, 2026
- Investigational RSV vaccine MV-012-968 (Dosage 2)Phase 1 · Respiratory Syncytial Virus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Investigational RSV vaccine MV-012-968 (Dosage 2)Phase 1 · Respiratory Syncytial Virus (RSV)ClinicalTrials.gov · fetched Nov 12, 2026
- Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)Phase 1 · Respiratory Syncytial Virus (RSV)ClinicalTrials.gov · fetched Nov 12, 2026
- Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)Phase 1 · Respiratory Syncytial Virus (RSV)ClinicalTrials.gov · fetched Nov 12, 2026
- Investigational RSV vaccine MV-012-968 (Dosage 3)Phase 1 · Respiratory Syncytial Virus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal DropsPhase 1 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal DropsPhase 1 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal DropsPhase 1 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal DropsPhase 1 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
- RSV vaccine MV-012-968 (dosage #1)Phase 1 · Respiratory Syncytial Virus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- RSV vaccine MV-012-968 (dosage #2)Phase 1 · Respiratory Syncytial Virus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 MonthsPHASE1 · UNKNOWN · started Jun 3, 2021ClinicalTrials.gov NCT04909021 · fetched Nov 12, 2026
- Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in AdultsPHASE1 · UNKNOWN · started Apr 12, 2021ClinicalTrials.gov NCT04798001 · fetched Nov 12, 2026
- Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive ChildrenPHASE1 · COMPLETED · started Jun 9, 2020ClinicalTrials.gov NCT04444284 · fetched Nov 12, 2026
- Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy AdultsPHASE1 · COMPLETED · started Jan 14, 2020ClinicalTrials.gov NCT04227210 · fetched Nov 12, 2026